Latest Corporate News

Pharmascience Inc launches (Pr)pms-TRANDOLAPRIL, first generic bioequivalent to (Pr)MAVIK available on the market, for the treatment of mild to moderate essential hypertension

 

Successful FDA Inspection of our Bioanalytical Laboratory

 

Pharmascience Inc. Launches (Pr)pms-NITROFURANTOIN, First Generic Bioequivalent to MacroBID® Available on the Market, for the Treatment of Urinary Tract Infections